Join to View Full Profile
1 Medical Center BlvdSuite Acp #533Chester, PA 19013
Phone+1 610-874-1184
Fax+1 610-874-4258
Are you Dr. Malamut?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Richard Malamut, MD is a board certified neurologist in Chester, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.
Education & Training
University of Pennsylvania Health SystemResidency, Neurology, 1986 - 1989- University of Pennsylvania Health SystemInternship, Internal Medicine, 1985 - 1986
Drexel University College of MedicineClass of 1985
Certifications & Licensure
PA State Medical License 1986 - 2026
American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 1 citationsEffect of Food on the Pharmacokinetics of Single- and Multiple-Dose Hydrocodone Extended Release in Healthy Subjects.Mary Bond, Laura Rabinovich-Guilatt, Sally Selim, Mona Darwish, William Tracewell
Clinical Drug Investigation. 2017-09-25 - 2 citationsEvaluation of Quality of Life, Functioning, Disability, and Work/School Productivity Following Treatment with an Extended-Release Hydrocodone Tablet Formulated with Ab...Martin E. Hale, Thomas R Zimmerman, Yuju Ma, Richard Malamut
Pain Practice. 2017-02-01 - 7 citationsSix-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potentialMartin E. Hale, Yuju Ma, Richard Malamut
Journal of Opioid Management. 2016-03-01
Press Mentions
Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (Risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I DisorderFebruary 25th, 2025- Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (Risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I DisorderFebruary 25th, 2025
- Collegium Announces Publication of “Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza® ER” in Pain MedicineOctober 26th, 2020
- Join now to see all
